None listed
Conditions
Interventions
GROUP B Type of group
Patients will receive 4 weeks of standard therapy, ie with Symbicor® Turtohaler®80 / 4.5 mcg or 160 / 4.5 mcg, two inhalations in the morning and two in the night according to the previous requirements of inhaled corticosteroids. Patients who have been previously treated with budesonide 400 to
Sponsors
ASTRAZENECA - PERU,
Eligibility
Inclusion criteria
Inclusion criteria: Patients currently well managed with inhaled corticosteroids and long-acting bronchodilators, or patients currently controlled with inhaled corticosteroids and short-acting bronchodilators, who present a level of symptoms indicating the need to use additional therapy, in accordance with the guidelines of the National Institute of Heart, Lung and Blood (NHLBI) for the management of asthma.
Exclusion criteria
Exclusion criteria: 1) FEP 2,000 mcg of beclomethasone dlpropionate (BDP) or fluticasone propionate or> 1,600 mcg of budesonide 3) Current requirements for oral steroids or use of oral steroids> 10 days in the previous 3 months. 4) Current use of any p-blocking therapy (including eye drops). 5) Infections of the upper respiratory tract in the previous four weeks. 6) Severe cardiovascular disease or any other significant concomitant disease that may interfere with the conduct of the study 7) Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose. 8) Pregnancy, planned pregnancy or breastfeeding.
Countries
Bahrain, Bulgaria, Chile, Costa Rica, Dominican Republic, El Salvador, Guatemala, Israel, Kenya, Nigeria, Oman, Panama, Peru, Qatar, Slovenia, United Arab Emirates, Venezuela
Outcome results
None listed